Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Weight change and long-term cardiovascular outcomes in overweight and obese patients after acute coronary syndromes.

European heart journal open·2026
Same author

Impact of care reorganisation during COVID-19 waves on non-COVID-19 inpatients in a Swiss hospital: a retrospective cohort study.

Swiss medical weekly·2026
Same author

Environmental pollution, apolipoprotein A-1 autoantibodies and cardiovascular risk: evidence from a geospatial cross-sectional study.

Atherosclerosis plus·2026
Same author

Multi-biomarker approach for predicting cardiac magnetic resonance parameters at 30 days after ST-segment elevation myocardial infarction.

International journal of cardiology. Heart & vasculature·2026
Same author

[Cardiology : what's new in 2025].

Revue medicale suisse·2026
Same author

[Cardiology : new 2025 guidelines].

Revue medicale suisse·2026

Related Experiment Video

Updated: Jul 12, 2025

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

1.9K

[Acetazolamide in acute heart failure].

Mickaël Jolti1, Pauline Darbellay Farhoumand1, David Carballo2

  • 1Service de médecine interne générale, Hôpitaux universitaires de Genève, 1211 Genève 14.

Revue Medicale Suisse
|October 25, 2023
PubMed
Summary

Acetazolamide speeds up decongestion in acute heart failure patients when added to standard diuretic care. This approach offers a safe and effective way to improve outcomes and reduce hospital readmissions for heart failure patients.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:15

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

75

Related Experiment Videos

Last Updated: Jul 12, 2025

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

1.9K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:15

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

75

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Acute heart failure (AHF) is a major cause of hospitalization, posing significant economic and public health challenges.
  • Current management of AHF primarily relies on diuretics to alleviate congestion, but many patients experience incomplete decongestion, increasing rehospitalization risk.

Purpose of the Study:

  • To evaluate the efficacy and safety of acetazolamide as an adjunct therapy to loop diuretics for decongestion in patients with acute heart failure.

Main Methods:

  • A multicenter randomized controlled trial was conducted.
  • Patients received either standard care with loop diuretics or standard care plus acetazolamide.
  • Decongestion was assessed using a pragmatic clinical score.

Main Results:

  • The addition of acetazolamide resulted in significantly faster decongestion compared to standard care alone.
  • The adjunctive use of acetazolamide demonstrated a favorable safety profile with minimal side effects.
  • Faster decongestion may lead to improved patient outcomes and reduced healthcare resource utilization.

Conclusions:

  • Acetazolamide is a safe and effective option for enhancing decongestion in acute heart failure patients.
  • Incorporating acetazolamide into standard treatment protocols could improve clinical outcomes and reduce hospital readmissions for acute heart failure.